Aciex Respiratory Therapeutics
Redevelop novel form of fluticasone (API in $1 billion Flovent) from BID to QD asthma product via 505(b)2 FDA pathway w/ new 20-year IP life
We develop market leading respiratory drugs, combining newly improved compounds with high performance respiratory inhalers to make transformational pulmonary therapies. Our products are cost effective to produce and efficient to distribute. Serves unmet asthmatic & pediatric populations in in US & ROW. Novel single-unit dose improves patient outcomes & overcomes problems of conventional treatments, including contamination, cross-use and loss.